Abstract
Using a panel dataset of 78 branded drugs for the period January 2009 through March 2020, we examine whether brand prices react to the onset of generic competition. Contrary to the findings of several prior academic studies, we show that the rate of change of brand prices (both nominal and CPI-deflated) are significantly lower after generics enter the market; notably, we also find branded drug manufacturers raise their prices in the six-month period just before generic entry and lower them in the six-month period after, with the differences in the rates of change being highly significant. We also show in markets with an authorized generic and in ones with large pre-entry brand sales, manufacturers raise prices at a higher (or decrease CPI-deflated prices at a shallower) rate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of the Economics of Business
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
